HER2 phosphorylates p66Shc at Tyr349, promoting its mitochondrial localisation and ROS production, which amplifies the MAPK/ERK and PI3K/Akt pathways, leading to proliferation and trastuzumab resistance in HER2‐positive cancers. Here, MAPK1 is linked to cancer.